- Abstract
- Core Tip
- Article Highlights
- Full Article with Cover (PDF)
- Full Article (HTML)
- Audio
- PubMed Central
- PubMed
- CrossRef
- Google Scholar
- Similar Articles (2330)
- Timeline of Article Publication (3)
- Authors Evaluation (1)
- Article Quality Tracking (1)
- Reader Comments (3)
- Reference Citation Analysis (0)
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6637)
All Articles published online
|
Publishing Process of This Article
|
May 7, 2021 (publication date) through Feb 18, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Yang DH, Wang WP, Zhang Q, Pan HY, Huang YC, Zhang JJ. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study. World J Gastroenterol 2021; 27(17): 2025-2038 [PMID: PMC8108039 DOI: 10.3748/wjg.v27.i17.2025] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v27/i17/2025.htm |
| Number | Citing Articles |
| 1 |
Zhiyong Du, Shengju Yin, Bing Liu, Wenxin Zhang, Jiaxu Sun, Meng Fang, Yisheng Xu, Kun Hua, Pengfei Tu, Guoliang Zhang, Ying Ma, Yingyuan Lu. Metabolomics and network analysis uncovered profound inflammation-associated alterations in hepatitis B virus-related cirrhosis patients with early hepatocellular carcinoma. Heliyon 2023; 9(5): e16083 doi: 10.1016/j.heliyon.2023.e16083
|
| 2 |
Zehong Wang, Xuanxuan Wang, Li Zhou, Shaoyuan Shi, Yongli Hua, Yinong Feng. Safety and efficacy of 48-week pegylated interferon-α-2b therapy in patients with hepatitis B virus-related compensated liver cirrhosis: a pilot observational study. Frontiers in Medicine 2024; 11 doi: 10.3389/fmed.2024.1489671
|
| 3 |
Yanhui Shi, Hongli Yang, Xue Bai, Xiaoyan Liu, Qiang Li, Wenjun Du. Female and diabetes are risk factors for alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II negative in hepatocellular carcinoma. Medicine 2024; 103(42): e40100 doi: 10.1097/MD.0000000000040100
|